{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:55:56Z","timestamp":1789430156756,"version":"build-2803163510"},"reference-count":17,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Thymic neuroendocrine neoplasms (t-NENs) are rare, biologically aggressive malignancies of the anterior mediastinum. Due to their low incidence, clinical evidence remains limited, and treatment recommendations are primarily based on expert opinion and extrapolation from other neuroendocrine tumors. This study aimed to analyze the clinicopathological features, treatment patterns, and survival outcomes of patients with t-NENs treated at a single comprehensive cancer center over 25 years. Methods: A retrospective review was performed on 19 adult patients diagnosed with t-NENs between 2000 and 2024. Data on demographics, histology, treatment intent, modalities used, and outcomes were collected. Survival analyses\u2014of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS)\u2014were conducted using the Kaplan\u2013Meier method. Results: The median age was 52 years; 63% of patients were male. Atypical carcinoid was the most common histologic subtype (52.6%), followed by large cell neuroendocrine carcinoma (31.6%). Paraneoplastic syndromes, including Cushing\u2019s syndrome, were observed in 26.3% of cases. Radical surgery was performed for 8 patients, but R0 resection was achieved in only 25% of them. Postoperative radiotherapy and chemotherapy were used for 36.8% and 15.8% of patients, respectively. Disease recurrence occurred in 44.4% of curatively treated patients. The median OS for the entire cohort was 127 months; patients treated with curative intent had a significantly longer OS (170 months) compared to those after palliative treatment (33 months). Median PFS in the palliative group was 11 months. Conclusions: t-NENs are aggressive tumors with high risk of recurrence and limited systemic treatment efficacy. Complete surgical resection remains the cornerstone of curative therapy. However, the overall prognosis remains poor, emphasizing the need for novel therapeutic strategies and prospective multicenter studies.<\/jats:p>","DOI":"10.3390\/cancers17243932","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:54:55Z","timestamp":1765274095000},"page":"3932","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinicopathologic Characteristics, Treatment Outcomes, and Survival in Thymic Neuroendocrine Neoplasms (t-NEN): A 25-Year Single-Center Experience"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-1772","authenticated-orcid":false,"given":"Aleksandra","family":"Pi\u00f3rek","sequence":"first","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3710-6445","authenticated-orcid":false,"given":"Adam","family":"P\u0142u\u017ca\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9452-3229","authenticated-orcid":false,"given":"Dariusz M.","family":"Kowalski","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3324-0900","authenticated-orcid":false,"given":"Maciej","family":"Krzakowski","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00428-021-03037-1","article-title":"Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus","volume":"478","author":"Bohnenberger","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13023-022-02366-x","article-title":"Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: A retrospective single-institution analysis","volume":"17","author":"Chen","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12020-022-03099-4","article-title":"Thymic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1","volume":"77","author":"Yliaska","year":"2022","journal-title":"Endocrine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1210\/jc.2004-1155","article-title":"Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: The Italian series","volume":"90","author":"Ferolla","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.athoracsur.2012.03.062","article-title":"Primary neuroendocrine tumors of the thymus: A multicenter experience of 35 patients","volume":"94","author":"Cardillo","year":"2012","journal-title":"Ann. Thorac. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2019.04.015","article-title":"Molecular Classification of Neuroendocrine Tumors of the Thymus","volume":"14","author":"Dinter","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cheng, Z., Yu, F., Chen, R., Cui, L., Chen, Y., Deng, C., Shi, Y., and Tan, H. (2024). Treatment, Prognostic Markers, and Survival in Thymic Neuroendocrine Tumors, with Special Reference to Temozolomide-Based Chemotherapy. Cancers, 16.","DOI":"10.3390\/cancers16142502"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtcvs.2014.08.061","article-title":"Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases","volume":"149","author":"Filosso","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40618-022-01961-w","article-title":"Sporadic and MEN1-related gastrinoma and Zollinger-Ellison syndrome: Differences in clinical characteristics and survival outcomes","volume":"46","author":"Massironi","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhai, Y., Zeng, Q., Bi, N., Zhou, Z., Xiao, Z., Hui, Z., Chen, D., Wang, L., Wang, J., and Liu, W. (2022). A Single Center Analysis of Thymic Neuroendocrine Tumors. Cancers, 14.","DOI":"10.3390\/cancers14194944"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors: A SEER database analysis of 160 patients","volume":"251","author":"Gaur","year":"2010","journal-title":"Ann. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1309\/3PDN-PMT5-EQTM-H0CD","article-title":"Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases","volume":"114","author":"Moran","year":"2000","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1378\/chest.124.1.141","article-title":"A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus","volume":"124","author":"Tiffet","year":"2003","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.lungcan.2012.12.001","article-title":"Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre","volume":"79","author":"Crona","year":"2013","journal-title":"Lung Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/1759-7714.12868","article-title":"Evaluation of the prognostic value of surgery and postoperative radiotherapy for patients with thymic neuroendocrine tumors: A propensity-matched study based on the SEER database","volume":"9","author":"Wen","year":"2018","journal-title":"Thorac. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Garcia-Torralba, E., Garcia-Lorenzo, E., Doger, B., Spada, F., and Lamarca, A. (2024). Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut. Cancers, 16.","DOI":"10.3390\/cancers16142530"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/3932\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:24:39Z","timestamp":1765275879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/3932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":17,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17243932"],"URL":"https:\/\/doi.org\/10.3390\/cancers17243932","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}